Quizartinib companion diagnostic - Daiichi Sankyo/Genoptix

Drug Profile

Quizartinib companion diagnostic - Daiichi Sankyo/Genoptix

Alternative Names: AC220 companion diagnostic

Latest Information Update: 18 Nov 2014

Price : $50

At a glance

  • Originator Genoptix
  • Developer Daiichi Sankyo Company; Genoptix
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Acute myeloid leukaemia

Most Recent Events

  • 10 Nov 2014 Ambit Biosciences Corporation has been acquired by Daiichi Sankyo Company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top